This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

CADASIL CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F01.1 | Special Copayment Reduction: V122
B. SynonymsCADASIL, subcortical ischemic vascular dementia, hereditary small vessel stroke, NOTCH3-related cerebral arteriopathy
C. Adult onsetLikelihood of first onset in adulthood high — sequentially presents with migraine (30s), TIA/cerebral infarction (40s~50s), and cognitive impairment (50s~60s); a typical adult-onset disease
1. History1977: first case report; 1993: Tournier-Lasserve established the name CADASIL; 1996: identification of the NOTCH3 gene
2. CausesDeposition of NOTCH3 ECD in smooth muscle cells of small vessel walls due to NOTCH3 gene mutations, with structural destruction of cerebral small arteries
3. GeneticsAutosomal dominant; NOTCH3 gene 19p13.2-p13.1; most are cysteine residue variants in the EGF-like repeat region
4. EpidemiologyEstimated worldwide prevalence about 50,000~100,000 people, 2~5 per 100,000 population; occurs in multiple ethnicities; an important cause of stroke in people in their 40s
5. PathophysiologyAbnormal extracellular deposition of NOTCH3 ECD → increased basement membrane thickness, degeneration of vascular smooth muscle cells → narrowing of the small artery lumen → recurrent subcortical infarcts
6. SymptomsMigraine with aura, recurrent transient ischemic attacks (TIA)/cerebral infarction, psychiatric·mood disorders, progressive cognitive decline, gait disturbance
7. SignsHemiplegia, dysarthria, dysphagia, impaired frontal executive function, gait abnormality, MRI white matter hyperintense lesions
8. ScreeningFamily history investigation, brain MRI (FLAIR white matter hyperintensities, subcortical infarcts), NOTCH3 genetic testing, skin biopsy
9. DiagnosisConfirmation of a NOTCH3 gene mutation or confirmation of GOM deposits in small arteries on electron microscopy of a skin biopsy
10. TreatmentNo curative treatment; prevention of cerebral infarction (antiplatelets), migraine management (acetazolamide, valproate), risk factor control
11. PrognosisSevere dementia and inability to walk within 20~30 years of onset, mean age at death early 60s; large interindividual variation
12. PreventionFamily genetic screening, management of cerebrovascular risk factors, smoking cessation, preimplantation genetic diagnosis
13. ReferencesChabriat et al. Lancet Neurol 2009 and 9 other papers

1. History

The history of CADASIL began in 1977, when it was first described in Germany as clustered cases within a family with recurrent strokes and dementia. In 1976, a similar family was also reported in France, and at the time it was presumed to be a hereditary ischemic stroke syndrome or a type of leukodystrophy. In the early 1990s, a French research team led by Marie-Germaine Bousser and Elisabeth Tournier-Lasserve systematically analyzed several families, established it as an independent genetic disease, and in 1993 formally proposed the current name, CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy).

In 1996, Joutel et al. discovered through linkage analysis and positional cloning that the causative gene of CADASIL is NOTCH3, located on chromosome 19p13. It was shown to be a member of the Notch receptor family important in cell signaling and development, expressed mainly in vascular smooth muscle cells of cerebral small arteries. Subsequently, electron microscopy studies confirmed that granular osmiophilic material (GOM) is deposited in the extracellular matrix of vascular smooth muscle cells of CADASIL patients, and GOM was shown to consist of abnormal accumulations of the NOTCH3 extracellular domain (ECD). Today, CADASIL is known as the most common hereditary small vessel stroke syndrome in humans.

2. Causes

The direct cause of CADASIL is pathogenic mutations in the NOTCH3 gene, which cause the extracellular domain (ECD) of the NOTCH3 protein to accumulate abnormally around vascular smooth muscle cells in the walls of cerebral small arteries and small vessels. NOTCH3 has an extracellular domain composed of 33 EGF-like repeat domains, and pairs of cysteine residues within each repeat form disulfide bonds that maintain the three-dimensional structure.

CADASIL-related mutations almost without exception cause the addition (resulting in an odd number) or removal of these cysteine residues, disrupting disulfide bond pairs within the NOTCH3 ECD. As a result, the protein is transformed into an abnormal structure and aggregates outside vascular smooth muscle cells as GOM (granular osmiophilic material). GOM can be identified by electron microscopy and causes increased vascular basement membrane thickness, degeneration and loss of smooth muscle cells, and narrowing of the small artery lumen, reducing cerebral perfusion. This process is the fundamental mechanism of recurrent subcortical ischemic infarcts and extensive white matter degeneration.

3. Genetics

CADASIL is inherited in an autosomal dominant manner, and the causative gene is NOTCH3, located on chromosome 19p13.2-p13.1. The NOTCH3 gene consists of 33 exons and encodes a protein of 2,321 amino acids. Mutations are concentrated mainly in exons 2~24, which encode the EGF-like repeat domains, and exons 3, 4, 5, and 6 in particular are known as mutation hotspots.

More than about 95% of pathogenic mutations are missense variants causing gain or loss of a cysteine residue within an EGF-like repeat. This cysteine residue change criterion is central to the pathogenicity classification of mutations for CADASIL diagnosis, and variants that do not alter cysteine are classified as having low or uncertain pathogenicity. More than 300 mutations have been reported worldwide, and mutations predominant in particular regions reflect founder effects (e.g., R544C, R182C, etc. are relatively frequent in Korea).

Penetrance is very high, and almost all mutation carriers experience clinical symptoms at least once in their lifetime, but there is considerable intraindividual·intrafamilial variation in phenotypic severity and age of onset. Modifier genes or vascular risk factors (hypertension, diabetes, smoking) have been proposed to contribute to phenotypic heterogeneity.

4. General epidemiology

CADASIL is the most common monogenic cerebral small vessel disease in the world, with an estimated worldwide prevalence of about 2~5 per 100,000 population. However, the actual prevalence is considered higher because of underdiagnosis and phenotypic heterogeneity. Some population-based studies have also reported estimates that the prevalence may exceed 10 per 100,000.

CADASIL is not limited to particular ethnic groups and occurs in all ethnicities and races. Many case studies have accumulated in Europe (France, the UK, Germany, Italy), and the number of cases is also increasing in Asia (Japan, Korea, China, Taiwan). In Korea, case reports have increased since the early 2000s, and the spectrum of NOTCH3 mutations is known to differ partly from that in Europe. The age of onset is concentrated in middle adulthood, with a mean of 26~35 years for migraine and 40~50 years for cerebral infarction. There is no clear sex difference, and men and women are equally affected.

5. Pathophysiology

The pathophysiology of CADASIL stems from abnormal extracellular accumulation of NOTCH3 ECD. Normal NOTCH3 performs a signaling function in which, upon ligand binding, the intracellular domain is cleaved and acts as a transcription factor in the nucleus, but in CADASIL mutations, the ECD accumulates as insoluble aggregates (GOM) around the basement membrane of vascular smooth muscle cells (VSMC).

GOM deposition causes increased thickness and altered composition of the vascular basement membrane, which interferes with the oxygen and nutrient supply of smooth muscle cells and leads to progressive VSMC degeneration and loss. NOTCH3 ECD accumulation is also known to disturb the normal differentiation and survival signals of VSMCs. These structural vascular changes impair the autoregulatory capacity of cerebral small arteries (cerebrovascular autoregulation), leading to reduced cerebral perfusion reserve (cerebrovascular reactivity).

Consequently, recurrent ischemic infarcts occur in the terminal small arteries supplying the deep cerebral white matter and basal ganglia, and extensive white matter demyelination (leukoencephalopathy) due to chronic ischemia progresses. It shows a characteristic distribution pattern in which the white matter of the external capsule, frontal white matter, and temporal pole is involved early, appearing as hyperintense lesions on FLAIR MRI. Microbleeds are also commonly present and are a risk factor for hemorrhagic complications.

6. Symptoms

The clinical symptoms of CADASIL generally consist of four main syndromes that appear sequentially. First, migraine with aura is the earliest symptom, occurring in about 20~40% of patients with a mean age of onset of 26~35 years. Migraine with visual aura is particularly frequent, and auras may be prolonged or complex (hemiplegic aura, sensory aura, etc.).

Second, recurrent ischemic stroke and transient ischemic attack (TIA) appear on average in the 40s~50s, with each attack presenting as a focal neurological deficit due to a small subcortical infarct. Hemiplegia, dysarthria, and sensory disturbances are common, and CADASIL should be strongly suspected when recurrent strokes occur in relatively young patients without classic stroke risk factors such as hypertension, diabetes, and atrial fibrillation.

Third, psychiatric·behavioral disorders reported include depression, apathy, anxiety, and mania, occurring in 20~40% of patients. In some, episodes of acute encephalopathy present in a way that requires differentiation from migraine. Fourth, cognitive decline becomes prominent from the 50s~60s, characterized by impairment of frontal executive function, attention, and processing speed. As it progresses it develops into vascular dementia, ultimately reaching a state of complete dependence with severe dementia, inability to walk, and urinary incontinence.

7. Signs

On physical examination, neurological abnormalities may be absent or mild initially. After cerebral infarction, hemiplegia, hemisensory disturbance, dysarthria, dysphagia, and ocular motility abnormalities may appear depending on the site of each infarct. When pseudobulbar palsy gradually develops due to recurrent subcortical infarcts, forced crying/laughing, difficulty swallowing, and severe dysarthria appear.

On cognitive testing, impairment of frontal executive function (planning, working memory, attention shifting) is more prominent than memory impairment initially. Gait examination shows a small-stepped frontal gait disorder, and impaired balance increases the risk of falls. Reflex examination may show lower extremity hyperreflexia and pathological reflexes (Babinski sign).

Brain MRI (FLAIR imaging) provides the most important imaging signs. Extensive periventricular and subcortical white matter hyperintense lesions (leukoaraiosis) and subcortical infarcts of various sizes in the basal ganglia, thalamus, and brainstem are observed. Involvement of the external capsule and temporal pole white matter are imaging findings highly specific for CADASIL and are important in differentiating it from small vessel disease of other causes. Multiple cerebral microbleeds may be identified on susceptibility-weighted imaging (SWI).

8. Screening

CADASIL is suspected and screening begins when unexplained stroke at a young age (40~55 years) or recurrent TIA, and a history of migraine with aura and cerebrovascular disease cluster within the same family. Ideally, the family history investigation structurally confirms histories of stroke, dementia, and migraine across three or more generations.

Brain MRI (3T recommended) is the most important screening tool. Extensive white matter hyperintensities including involvement of the external capsule and temporal pole on FLAIR, multiple subcortical infarcts, and a microbleed pattern on SWI strongly suggest the diagnosis of CADASIL. When MRI findings are typical and there is an appropriate family history, it is efficient to perform NOTCH3 genetic testing first.

NOTCH3 genetic testing is performed by Sanger sequencing or an NGS panel covering exons 2~24, with the aim of identifying a pathogenic cysteine variant. Electron microscopy of a skin biopsy (confirming GOM deposits around VSMCs) is used as an adjunctive diagnostic method when genetic test results are uncertain or access is difficult. Cognitive testing (MMSE, MoCA, FAB) and neuropsychological testing are essential for establishing a baseline of cognitive decline and for follow-up.

9. Diagnosis

Confirmation of CADASIL is made by two main methods. The first is molecular genetic confirmation of a pathogenic mutation altering a cysteine residue within an EGF-like repeat in exons 2~24 of the NOTCH3 gene. NGS-based gene panel testing is recommended because it can cover all known mutation regions in a single test. Because the pathogenicity of NOTCH3 variants not involving a cysteine change requires separate functional evidence, they must be interpreted together with the clinical phenotype and MRI findings.

The second is confirming characteristic GOM deposits around VSMCs on electron microscopy of a skin biopsy. The skin biopsy is taken by 4~5mm punch biopsy from the lateral upper arm, using glutaraldehyde fixative for electron microscopy preparation. GOM is identified as granular electron-dense material of 1~3 nm aggregated within the basement membrane of vascular smooth muscle cells. The sensitivity of a GOM-positive skin biopsy is about 45~65%, lower than genetic testing, but it is important as complementary evidence when genetic testing is not possible or a variant of uncertain pathogenicity is detected.

Clinical diagnostic algorithm: typical MRI findings + appropriate family history → NOTCH3 genetic testing → confirmed if a cysteine-altering mutation is identified. Negative genetic testing or a variant of uncertain pathogenicity → skin biopsy electron microscopy → GOM positivity supports the clinical diagnosis. Presymptomatic carrier testing is performed after adequate genetic counseling.

10. Treatment

Currently, no standard treatment has been established that treats the underlying cause of CADASIL or suppresses its progression. Treatment is a symptomatic·preventive approach centered on symptom management, stroke prevention, and risk factor control.

Stroke prevention

The efficacy of antiplatelet agents (aspirin, clopidogrel) in CADASIL has not been proven in clinical trials, but their use after TIA or ischemic stroke can be considered in line with general small vessel stroke prevention. However, when cerebral microbleeds or hemorrhagic infarction are present, the bleeding risk of antiplatelet use must be carefully reviewed. Anticoagulants are generally not recommended. Thrombolytic therapy (t-PA) is not an absolute contraindication in acute ischemic attacks, but the risk is assessed individually when multiple microbleeds are present.

Migraine management

Acetazolamide may be used as preventive treatment, as there are observational reports of its efficacy for CADASIL migraine. Sodium valproate, lamotrigine, topiramate, verapamil, and flunarizine are also used as alternative preventive treatments. Contrary to theoretical concerns, the safety of triptans in CADASIL patients has recently been supported in observational studies, so their use for acute migraine attacks may be considered. Ergotamines should be avoided because of their vasoconstrictive effects.

Cognitive function and behavioral disorders

Donepezil did not meet the primary endpoint (global cognitive function) in a phase 3 clinical trial, but some improvement in executive function was reported, and it is used in some patients. Selective serotonin reuptake inhibitors (SSRIs) may be used for depression and apathy. Rehabilitation (speech therapy, physical therapy, occupational therapy) is a key non-pharmacological intervention for maintaining function.

Risk factor control

Active management of vascular risk factors such as hypertension, hyperlipidemia, diabetes, and smoking is important for suppressing stroke recurrence and delaying cognitive decline. Specifically, blood pressure control targeting a systolic blood pressure below 130 mmHg is recommended. Smoking cessation is an essential measure to suppress the progression of small vessel disease.

11. Prognosis

CADASIL is a progressive disease that, without treatment, leads to severe dementia and physical disability over decades. In large cohort studies, the mean survival after onset is reported as about 64 years in men and about 69 years in women, shortened by about 10 years on average compared with the general population. Causes of death are mainly complications of prolonged bedridden status, such as aspiration pneumonia and pressure ulcer infection, and there are also deaths from heart disease or hemorrhagic stroke.

There is considerable intraindividual·intrafamilial heterogeneity in age of onset and clinical severity. Even within the same family, cases with onset in the 30s and rapid progression may coexist with cases showing only mild symptoms into the 60s. This variability is presumed to be influenced by the location and type of the NOTCH3 mutation, the burden of vascular risk factors, and modifier genes. When extensive white matter hyperintensities and multiple subcortical infarcts are seen on brain MRI from early on, cognitive decline and functional impairment progress more rapidly.

Even in asymptomatic mutation carriers, brain MRI abnormalities begin to appear from the 30s, and subtle cognitive decline may be identified on neuropsychological testing before clinical symptoms appear. Therefore, regular neurological and cognitive follow-up of carriers is important.

12. Prevention

There is currently no prevention method that prevents the onset of CADASIL itself. However, prevention strategies to slow disease progression and reduce complications are important. Through stepwise NOTCH3 genetic testing (cascade testing) of first-degree relatives of confirmed patients and genetic counseling, asymptomatic carriers are detected early, and plans for cerebrovascular risk factor control and regular follow-up are established.

Early detection and active management of vascular risk factors (hypertension, diabetes, hyperlipidemia, smoking, obesity) is the key prevention strategy for suppressing stroke recurrence and cognitive decline in CADASIL patients. In particular, smoking aggravates cerebral small vessel damage, so smoking cessation must be advised. Excessive drinking should also be avoided. Regular aerobic exercise may help maintain cerebral perfusion reserve, but caution is needed because excessively intense exercise or dehydration can increase the risk of infarction.

During pregnancy, the risks of gestational hypertension, eclampsia, and the like may be higher than in other women, and neurological monitoring is needed around delivery. Carrier couples planning to have children can be offered preimplantation genetic testing (PGT) and prenatal diagnosis. Integrated management through a multidisciplinary approach (neurology, rehabilitation medicine, psychiatry, genetic counselor) is essential for improving the quality of life of patients and families.

13. References

  1. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643-653. doi:10.1016/S1474-4422(09)70127-9. PMID: 19539236.
  2. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6601):707-710. PMID: 8878478.
  3. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44(5):731-739. PMID: 9818926.
  4. Pescini F, Nannucci S, Bertaccini B, et al. The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. Stroke. 2012;43(11):2871-2876. PMID: 23033343.
  5. Rutten JW, Klever RR, Hegeman IM, et al. The NOTCH3 extracellular domain; a mission critical protein in CADASIL. Biochim Biophys Acta. 2014;1842(7):1066-1075. PMID: 24384525.
  6. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127(Pt 11):2533-2539. PMID: 15385584.
  7. Meschia JF. CADASIL: inherited risk for ischemic stroke. Stroke. 2003;34(4):1024-1029. PMID: 12649517.
  8. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7(4):310-318. PMID: 18296124.
  9. Herve D, Chabriat H. CADASIL. J Geriatr Psychiatry Neurol. 2010;23(4):269-276. PMID: 20938043.
  10. Hack RJ, Rutten JW, Lesnik Oberstein SAJ. CADASIL. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington; 2000 [updated 2019]. PMID: 20301390.